Literature DB >> 14651848

Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress.

Tony T Huang1, Shelly M Wuerzberger-Davis, Zhao-Hui Wu, Shigeki Miyamoto.   

Abstract

The transcription factor NF-kappaB is critical for setting the cellular sensitivities to apoptotic stimuli, including DNA damaging anticancer agents. Central to NF-kappaB signaling pathways is NEMO/IKKgamma, the regulatory subunit of the cytoplasmic IkappaB kinase (IKK) complex. While NF-kappaB activation by genotoxic stress provides an attractive paradigm for nuclear-to-cytoplasmic signaling pathways, the mechanism by which nuclear DNA damage modulates NEMO to activate cytoplasmic IKK remains unknown. Here, we show that genotoxic stress causes nuclear localization of IKK-unbound NEMO via site-specific SUMO-1 attachment. Surprisingly, this sumoylation step is ATM-independent, but nuclear localization allows subsequent ATM-dependent ubiquitylation of NEMO to ultimately activate IKK in the cytoplasm. Thus, genotoxic stress induces two independent signaling pathways, SUMO-1 modification and ATM activation, which work in concert to sequentially cause nuclear targeting and ubiquitylation of free NEMO to permit the NF-kappaB survival pathway. These SUMO and ubiquitin modification pathways may serve as anticancer drug targets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14651848     DOI: 10.1016/s0092-8674(03)00895-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  220 in total

Review 1.  Caspase-2: the orphan caspase.

Authors:  L Bouchier-Hayes; D R Green
Journal:  Cell Death Differ       Date:  2011-11-11       Impact factor: 15.828

2.  NF-κB in Aging and Disease.

Authors:  Jeremy S Tilstra; Cheryl L Clauson; Laura J Niedernhofer; Paul D Robbins
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

3.  CD2AP regulates SUMOylation of CIN85 in podocytes.

Authors:  Irini Tossidou; Rainer Niedenthal; Malte Klaus; Beina Teng; Kirstin Worthmann; Benjamin L King; Kevin J Peterson; Hermann Haller; Mario Schiffer
Journal:  Mol Cell Biol       Date:  2011-12-27       Impact factor: 4.272

4.  Alternative nuclear functions for NF-κB family members.

Authors:  Lluís Espinosa; Anna Bigas; Maria Carmen Mulero
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

5.  PIASy-mediated Tip60 sumoylation regulates p53-induced autophagy.

Authors:  Samisubbu R Naidu; Alexander J Lakhter; Elliot J Androphy
Journal:  Cell Cycle       Date:  2012-07-15       Impact factor: 4.534

Review 6.  "Without Ub I am nothing": NEMO as a multifunctional player in ubiquitin-mediated control of NF-kappaB activation.

Authors:  Jérémie Gautheron; Gilles Courtois
Journal:  Cell Mol Life Sci       Date:  2010-05-26       Impact factor: 9.261

7.  Inhibition of NF-kappaB activation with designed ankyrin-repeat proteins targeting the ubiquitin-binding/oligomerization domain of NEMO.

Authors:  Emanuel Wyler; Monika Kaminska; Yves-Marie Coïc; Françoise Baleux; Michel Véron; Fabrice Agou
Journal:  Protein Sci       Date:  2007-09       Impact factor: 6.725

Review 8.  Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2.

Authors:  H Christian Reinhardt; Michael B Yaffe
Journal:  Curr Opin Cell Biol       Date:  2009-02-21       Impact factor: 8.382

9.  SUMOylation attenuates sensitivity toward hypoxia- or desferroxamine-induced injury by modulating adaptive responses in salivary epithelial cells.

Authors:  Ha-Van Nguyen; Jo-Lin Chen; Jenny Zhong; Kwang-Jin Kim; Edward D Crandall; Zea Borok; Yuan Chen; David K Ann
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

10.  Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation.

Authors:  Ashish Jain; Chi A Ma; Eduardo Lopez-Granados; Gary Means; William Brady; Jordan S Orange; Shuying Liu; Steven Holland; Jonathan M J Derry
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.